Zymergen co-founders Zach Serber, Josh Hoffman, and Jed Dean (Zymergen via website)
August 4, 2021 04:02 PM EDTUpdated August 5, 03:52 AM
Financing

Zymer­gen's sud­den im­plo­sion shocked biotech. A lin­ger­ing loan could make things even worse

Kyle Blankenship

As for­mer syn­bio uni­corn Zymer­gen picks up the pieces from its spec­tac­u­lar im­plo­sion Tues­day, an out­stand­ing loan from Per­cep­tive Ad­vi­sors — the on­ly blue-chip biotech …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
TRENDING NOW

'Go ahead and do it': Top RFK Jr. deputy dares drug­mak­ers that might pull man­u­fac­tur­ing over new price pres­sure

The in­side sto­ry of the six-month sprint to cre­ate the first cus­tom CRISPR ther­a­py for one in­fant’s rare dis­ease

New CBER chief Prasad is ready­ing 'mas­sive frame­work' around vac­cines, Makary says

Bris­tol My­ers CEO says Amer­i­ca’s bio­phar­ma pole po­si­tion is not guar­an­teed

Ex­clu­sive: Drug com­pounder Em­pow­er was built on risky short­cuts, ex-em­ploy­ees and in­spec­tions al­lege

Eli Lil­ly turns to South Ko­re­an RNA edit­ing biotech for hear­ing loss in deal worth $1.3B

A service from the Financial Times